Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $182.5 million.

  • Prime Medicine's Cash & Equivalents fell 39.48% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year decrease of 39.48%. This contributed to the annual value of $182.5 million for FY2024, which is 338.92% up from last year.
  • As of FY2024, Prime Medicine's Cash & Equivalents stood at $182.5 million, which was up 338.92% from $41.6 million recorded in FY2023.
  • Prime Medicine's Cash & Equivalents' 5-year high stood at $187.6 million during FY2022, with a 5-year trough of $37.0 million in FY2020.
  • In the last 3 years, Prime Medicine's Cash & Equivalents had a median value of $182.5 million in 2024 and averaged $137.2 million.
  • In the last 5 years, Prime Medicine's Cash & Equivalents soared by 401.47% in 2021 and then plummeted by 77.84% in 2023.
  • Over the past 5 years, Prime Medicine's Cash & Equivalents (Yearly) stood at $37.0 million in 2020, then spiked by 401.47% to $185.4 million in 2021, then grew by 1.19% to $187.6 million in 2022, then crashed by 77.84% to $41.6 million in 2023, then spiked by 338.92% to $182.5 million in 2024.